Trevena (NASDAQ: TRVN) is adding to early gains bolstered by positive analyst commentary and an upgrade at Barlclays. Shares are ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Momentum Movers

Barclays Upgrades Trevena (TRVN) to OverweightSeptember 1, 2015 10:44 AM Roth Capital Reiterates Buy on Trevena (TRVN) Following TRV130’s Phase 2b Results September 1, 2015 9:41 AM Needham & Company Reiterates Buy on Trevena (TRVN) Following Positive TRV130 Results September 1, 2015 8:45 AM Trevena (TRVN) PT Bumped to $14 at Cowen as TRV130 Shows Strong Safety And Efficacy ProfileSeptember 1, 2015 7:32 AM Trevena (TRVN) PT Raised to $20 at WedbushSeptember 1, 2015 6:44 AM Trevena (TRVN) Announces TRV130 Phase 2b Met Primary Endpoint in Acute Postoperative PainAugust 31, 2015 4:02 PM Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative PainAugust 31, 2015 4:01 PM